IGC PHARMA, INC.

IGC

CIK 0001326205 · Quarterly mode · latest period FY2025 (Q3) (ending 2025-09-30) · sourced from SEC EDGAR

At a glance · FY2025 (Q3)

Revenue
$191K
↓-53.6% -$221Kvs FY2024 (Q3)
Gross Profit
$99K
↓-50.0% -$99Kvs FY2024 (Q3)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
23/100
  • Profitability
    0ROIC -84.5% (10% = solid, 20%+ = moat)
  • Liquidity
    39Current Ratio 1.28 (above 1.5 = solid)
  • Leverage
    99D/E 0.02 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.14x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -53.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -1517.8% · trend -17.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$82K
investment in PP&E
Stock-based comp (TTM)
$5M
non-cash dilution

Balance sheet · 2025-09-30

latest filed snapshot
Total assets
$10M
everything owned
Total liabilities
$2M
everything owed
Stockholders' equity
$8M
shareholder claim
Net debt
$-973K
Net cash position ($973K)

Recent performance · 63 quarters

Revenue↓-53.6% -$221K
$191K
Net Income↓-6.1% -$104K
$-2M
Free Cash Flow↑+0.0% +$0
$-29K
Operating Margin↓-1090.6pts
-1517.8%

Drill down